Molecular Oncology Research Center - Hospital de … Molecular Oncology Research Center – Barretos...

3 Molecular Oncology Research Center – Barretos Cancer Hospital

Introduction

The Molecular Oncology Research Center “Centro de Pesquisa em Oncologia Molecular”

(CPOM) was inaugurated on August 19, 2010, by the former Minister of Health, Dr. José

Temporão. The CPOM is framed at the Institute for Research and Education “Instituto de

Ensino e Pesquisa” (IEP) of Barretos Cancer Hospital, which in conjunction with other clinical

departments of the Hospital, as well as the Department of Clinical Research and Post-

graduation in Oncology, are the basic foundations in developing the future of oncology

medicine - personalized medicine.

The CPOM is installed in the new building of the IEP, with an area of 1,000 m2. The project

design was based on the most modern research centers, emphasizing the convenience of

movement, sharing of technological resources and the supervision of experience

professionals. The complex infrastructure of CPOM counts with state-of-the-art laboratories

of cytogenetics, molecular genetics, and molecular and cellular biology, allowing the

development of different research lines of in the field of molecular oncology.

During 2012, the second year of CPOM, we observed the growing of the projects generated

in the first year, and the implementation of numerous and varied scientific partnerships. A

significant number of researchers joined the Center, increasing its multidisciplinary, critical

mass and consequently productivity.

This year, the Hospital was included in the Outreach Program of St. Jude’s Children Hospital,

which will bring significant opportunities for research in pediatric oncology and has also

approved to be part of the International Cancer Genome Consortium (ICGC), an

international initiative to performed large scale next sequencing generation of cancer

worldwide, which puts the CPOM as a partner in a select group of institutions.


To evaluate and guide their steps, the CPOM was an External Advisory Board, which consists

of the following members:

- Jorge Reis-Filho (MSKCC, USA)

- Jorge Gomez (NCI, USA)

- Luisa Villa (INCT-CNPq, Brazil)

- Manuel Sobrinho-Simões (IPATIMUP, Portugal)

- Oliver Bogler (MDAnderson, USA)

1) Mission

To promote knowledge and innovation in order to apply molecular oncology in cancer

control.

- Knowledge of the causes, biological mechanisms and targets,

- Innovation in detection, diagnostic, treatment and prognosis,

- Application in prevention and assistance to patient.

2) Team

Senior Researcher

Adhemar Longatto Filho, PhD – Coordinator of Post-graduation

Andre Lopes Carvalho, PhD,MD – Executive Director IEP

Benedito Mauro Rossi, PhD,MD – External Collaborator

Ismael Dale Cotrim Guerreiro da Silva, PhD,MD – External Collaborator

José Humberto Tavares Guerreiro Fregnani, PhD, MD – Scientific Director of IEP

Luiz Fernando Lopes, PhD, MD – Coordinator of Pediatrics Department

Rui Manuel Reis, PhD, MD– Coordinator of CPOM

Visiting Professor

Kari J Syrianny, PhD, MD – Universidade de Turku, Kuusisto, Finlândia.

Jeremy Squire - Queens University, Kingston, Ontario, Canada

Junior Researcher

Cristovam Scapulatempo-Neto – Coordinator of Pathology Department

Daniel Onofre Vidal, PhD – Researcher CPOM

Denise Peixoto Guimarães, PhD, MD – Endoscopy Department


Edenir Palmero – Researcher CPOM

Henrique César S. Silveira– Researcher CPOM

Márcia Silveira – Researcher CPOM

Marjori Camparoto – Researcher CPOM

Vinicius Vazquez, PhD, MD – Skin Tumors Department

Post-doc

Adriane Feijó Evangelista, PhD

Ana Carolina Laus, PhD

Eduardo Anselmo Garcia, PhD

Fernanda Scarnato de Rosa, PhD

Lucas Tadeu Bidinotto, PhD

Olga Martinho, PhD

Vânia Sanmartino Mariano, PhD

Viviane Silva, PhD.

PhD Student

Adriana Tarlá Lorenzi

Aline Becker

Lidia Maria Rebolho Batista Arantes – external student

Ana Carolina Carvalho – external student

Master Student

Ana Laura Rodrigues Bordinhão

Augusto Ludvik Marino

Carla Aparecida Pinheiro

Croider Franco Lacerda

Flávia Coltri Eguchi

Letícia dos Santos Yamane

Maíra DeGiovani Stein

Natalia Campacci

Nathalia Campanella

Taciane Macedo

Biologist / Technician

Aline Tansine


Abel Feliciano de Queiroz Junior

Adriana Cruvinel Carloni (Master student)

Alessandra Paulino dos Santos

André Escremim de Paula

Carolina Dias Carlos (PhD student)

Eloisa Elena Faria Moreno

Deise Reis de Paula

Gabriela Carvalho Fernandes

Gustavo Noriz Berardinelli

Maicon Fernando Zanon da Silva (aluno de mestrado)

Marcela Nunes

Raul Torrieri

Renato José da Silva Oliveira (PhD student)

Valéria Mendes Motta

Research Initiation / Trainee

André de Lima Mota

Fatima Ramadan

Fernanda Cury

Graziela Sartori

Isabela de Carvalho

Juliana Oliveira de Lima

Lamis Ramadan

Talitha Lezaretti Blau

Administrative

Aline Cristina Morais – Assistant

Ednise Woyciechowski – Manager of IEP

Marcella Marchioretto – Financial Analyst of IEP

Osmar Alves – Informatics Technical Support

Raphael Ramos – Auxiliary

Rodolfo Massuda – Analyst

Paulo Ferreira – Marketing and Commercial


3) Research Lines

Cellular Signaling

One of the hallmarks of cancers is the oncogenic upregulation of the signaling cascades that

govern the transduction of extracellular growth factors to cellular nuclear response. Among

these plethora of players, receptor tyrosine kinases (RTKs) and intracellular MAPK,

PI3KCA/AKT and JAK/STAT pathways, have a crucial impact in cancer development, behavior

and currently, there is also an attractive therapeutic target. Our group is focused in evaluate

the major genetic alterations that disrupt these cellular circuits, and understand their

impact on patient prognosis and therapeutic response. Additionally, using tumor cell line

and primary culture models we intend to understand their function and biological impact on

cancer.

Biomarkers

We now know that cancer is a disease of the genome and this new vision has introduced a

new paradigm. In this scenario, the genome of the cancer can be more objectively in the

stratification of patients with cancer, leading to the emerging personalized medicine in

oncology. In order to achieve this aim, it is necessary to identify from the myriad of cancer

genomic changes, which ones have a clinical value - biomarkers. The diagnosis based on the

genome, it should present a high sensitivity and specificity, and detection of these

biomarkers should be possible not only in tumor tissue, but also extended to other body

fluids such as plasma, serum, urine, saliva, strokes cavity, allowing so early detection and

the ability to monitor tumor development. With a huge bank of tissues and fluids of cancer

patients in Barretos Hospital of Cancer (CrioBio) and a detailed medical history, our group

intends to validate potential biomarkers known in the Brazilian population, as well as

identify new biomarkers.

Functional Genomics of Cancer

The genomic science aims to understand how genes and genetic information is organized

within the genome (structural genomics) and how the organization determines its function

(functional genomics). The functional genomics applied to cancer aims to evaluate


systematically and simultaneously, the expression of genes (mRNA), microRNAs or proteins

to a better understanding of the molecular genetic basis governing the process of

carcinogenesis. Our research group intends to use the functional genomics resources for

transcriptional signatures mRNA and microRNAs expression in order to point out potential

molecular biomarkers of tumor progression. Additionally, using tumor cell line we can

validate the miRNA-mRNA interactions through functional tests using silencing of miRNAs

(using anti-miRNAs or anti-MIRs) and thus assess the impact of these new biomarkers in the

progression cancer.

Environmental factors and Cancer

The exposure to different types of environmental factors such as: food, occupational

conditions, medications, hormones, radiation, viruses, bacteria, chemical agents, air

pollution and water are intrinsically linked to the occurrence of cancer in exposed

populations. The determination of the potential cancer risk in the exposure to

environmental factors can contribute to public policies and preventive measures. Therefore,

our research group aims to assess populations exposed to chemical or environmental

factors using genetic biomarkers. Considering the susceptibility of each individual to

metabolize carcinogenic agents, we intend to reveal the molecular mechanisms involved in

the resistance to these compounds, polymorphisms, gene-environment interactions and its

implications in carcinogenesis.

Hereditary Cancer

Several cancers developed in higher than normal frequencies may be related to inherited

genetic alterations, present in predisposed families. Around 10% of most cancer types are

due to the presence of germline mutations, leading to an increased lifetime cancer risk. The

recognition of a hereditary cancer-affected individual is crucial for the identification of other

at-risk family members and their inclusion in cancer risk reduction strategies. The focus of

our research group is to prematurely identify, characterize and analyze, clinically and

molecularly, these at-risk individuals. Genetic modifiers that may contribute to an increased

cancer development risk, such as genetic polymorphisms, rearrangements, copy number

variations are also part of our research work.


-Epigenetic

Epigenetic are related to reversible events that do not produce modification in the genomic

DNA sequence, but rather alters its phenotype, influencing mechanisms related to gene

expression. Methylation is the most common epigenetic event, being a very important

biologic process involved in gene silencing. The study of hypermethylation can give vital

information on the understanding of carcinogenesis, as well as the evaluation of its pattern

can be used as a biomarker for diagnosis, treatment planning and prognosis of an individual.

Pediatric Tumor Biology

Although considered rare, childhood cancer is the leading cause of disease-related mortality

in children. Cancer in the childhood often is more devastating and aggressive than their

counterparts in adults. Despite the progress in cure rates and survival improvement

achieved in the last Decades, there is a group of tumors that still do not respond to any

available standard treatment. Our goal is to apply the knowledge and tools of molecular

biology to clarify and understand the biology and pathogenesis of pediatric tumors, in order

to identify potential biological markers that may support diagnosis and/or indicate

prognosis of pediatric patients. As well, we are looking for the altered pathways/genes that

can be targets for new therapy strategies

4) Productivity

4.1) Books or Book Chapters

1. Lopes LF, Almeida MTA. Tumores de Células Germinativas. In: Doenças neoplásicas da

criança e do adolescente, Editora Manole, pp.268-280, 2012.

2. Nogueira-de-Souza NC, Almeida JR, Serrano SV, Reis RM. BRAF in glioblastomas: clinical

implications. In: Glioblastoma: Risk Factors, Diagnosis and Treatment Options, Nova Science

Publishers, Inc, pp. 227-240, 2012.

3. Paixão Becker A, Caravina G, Clara C, Reis RM. The role of immunohistochemistry in the

diagnostic and prognostic of glioblastoma patients. In: Glioblastoma: Risk Factors, Diagnosis

and Treatment Options, Nova Science Publishers, Inc, pp. 173-199, 2012.


4. Viana-Pereira M, Jones C, Reis RM. Pediatric high grade glioma: role of microsatellite

instability. In “Diagnostic, Therapeutic and Prognostic: Pediatric Cancer”, vol 3, Part 4, 205-

210, 2012.

5. Vazquez VL, Serrano SV, Capuzzo R. Advanced squamous cell carcinoma of the skin. In:

Xiaoming Li. (Org.). Squamous Cell Carcinoma. 1ed.Rijeka: Intech, 2012, v. 01, p. 34-52.

6. Rossi BM, Ferreira FO, Silva FCC. Histórico, caracterização clínica e aspectos moleculares

da syndrome de Lynch. In: Tratado de Coloproctologia, Campos FGCM, Regadas FSP, Pinho

M. Atheneu, São Paulo, p.531-42, 2012.

4.2) Publications in international Journals

1. Almeida MI, Nicoloso M, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Bondaruk J, Fabbri M,

Czerniak B, Lanza G, Reis RM, Zweidler-McKay P, Calin GA. Strand-Specific miR-28-5p and

miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology. 2012 Apr;

142(4):886-896. IF: 12,032.

2. Almeida MI, Reis RM, Calin GA. Dec.oy activity through microRNAs: the therapeutic

implications. Expert Opin Biol Ther. 2012 Sep; 12(9):1153-9. IF: 3.505

3. Alves AL, Pereira CS, Carvalho Mde F, Fregnani JH, Ribeiro FQ. EGFR expression in

acquired middle ear cholesteatoma in children and adults. Eur J Pediatr. 2012

Feb;171(2):307-10.IF:1.879

4. Amorim R, Vilaca N, Martinho O, Reis RM, Sardo M, Rocha J, Fonseca AM, Baltazar F,

Neves IC. Zeolite structures loading with an anticancer compound as drug delivery systems.

Journal of Physical Chemistry C, 116, 48, 25642-25650, 2012. IF 4.805.

5. Begnami MD, Fregnani JH, Brentani H, Torres C, Costa WL Jr, Montagnini A, Nonogaki S,

Soares FA. Identification of protein expression signatures in gastric carcinomas using

clustering analysis. J Gastroenterol Hepatol. 2012 Feb;27(2):378-84. IF: 2.865.

6. Beldi MC, Tacla M, Caiaffa-Filho H, Ab'saber A, Siqueira S, Baracat EC, Alves VA, Longatto

Filho A. Implementing human papillomavirus testing in a public health hospital: challenges

and opportunities. Acta Cytologica. 2012; 56(2):160-5. IF: 0.488.

7. Bidinotto LT, Costa CA, Costa M, Rodrigues MA, Barbisan LS. Modifying Effects of

Lemongrass Essential Oil on Specific Tissue Response to the Carcinogen N-Methyl-N-

Nitrosurea in Female BALB/c Mice. J Med Food. 2012 Feb; 15(2):161-8. IF: 1.408.


8. Bidinotto LT, de Cicco RL, Vanegas JE, Santucci-Pereira J, Vanden Heuvel JP, Washington S,

Aliaga C, Xu H, Russo IH, Manni A, El-Bayoumy K, Russo J. Fish oil alters tamoxifen-

modulated expression of mRNAs that encode genes related to differentiation, proliferation,

metastasis, and immune response in rat mammary tumors. Nutr Cancer. 2012; 64(7):991-9

IF: 2,553.

9. Bravo-Calderón DM, Oliveira DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP.

Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma.

Cancer Biomark. 2011-2012 10 (1):51-9. IF: 1,078.

10. Campa D, Martino A, Sainz J, Buda G, García Jamroziak K, Weinhold N, Reis RM, García-

Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesuer F, Bugert P, Moreno V,

Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi

S, Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and

multiple myeloma risk in the IMMEnSE (International Multiple Myeloma rESEarch)

consortium. British Journal of Haematology, 2012 May; 157(3):331-8. IF: 4.941.

11. Cardeal LB, Boccardo E, Termini L, Rabachini T, Andreoli MA, di Loreto C, Longatto Filho

A, Villa LL, Maria-Engler SS. HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in

primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One.

2012;7(3):e33585.IF 4.092.

12. Costa WL, Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, Mello CA, Fanelli

MF, Silva MJ, Fregnani JH, Montagnini AL. Adjuvant chemoradiotherapy after d2-

lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. Results of a

single cancer center. Radiat Oncol. 2012 Oct 15;7(1):169. IF: 2.321.

13. da Cunha IW, De Brot L, Carvalho KC, Rocha RM, Fregnani JH, Falzoni R, Ferreira Fde O,

Aguiar S Jr, Lopes A, Muto NH, Reis LF, Soares FA, Vassallo J. Prognostication of soft tissue

sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-

2/neu, and survivin. Ann Surg Oncol. 2012 Jun; 19(6):1790-9. IF: 4.166.

14. de Carvalho AC, Kowalski LP, Campos AH, Soares FA, Carvalho AL, Vettore AL. Clinical

significance of molecular alterations in histologically negative surgical margins of head and

neck cancer patients. Oral Oncol. 2012 Mar; 48(3):240-8. IF: 2.857.

15. De Mello R, Costa BM, Reis RM, Hespanhol V. Insights into angiogenesis in non-small cell

lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent

Patents on Anti-Cancer Drug Discovery, 1; 7 (1):118-31. 2012. IF: 2.723.

http://www.ncbi.nlm.nih.gov/pubmed/23061905




16. De Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J,

Oliveira P, Hespanhol V, Reis RM. Association between EGF +61 genetic polymorphisms and

non-small cell lung cancer increased risk in a Portuguese population: a case-control study.

Tumour Biology. 2012 Oct; 33(5):1341-8. IF: 2.143.

17. De Molfetta GA, Ferreira CA, Vidal DO, de Rosso Giuliani L, Maldonado MJ, Silva WA Jr.

1031-1034delTAAC (Leu125Stop): a Novel Familial UBE3A Mutation Causing Angelman

Syndrome in Two Siblings showing Distinct Phenotypes. BMC Med Genet. 2012 Dec. 20;

13(1):124. IF: 2,328.

18. De Oliveira AT, Pinheiro C, Longatto Filho A, Brito MJ, Martinho O, Matos D, Carvalho

AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS, Reis RM, Baltazar F. Co-expression of

monocarboxylate transporter 1 (MCT1) with CD147 is associated with low survival in GIST

patients. Journal of Bioenergetics and Biomembranes, 2012 Feb; 44 (1):171-8. IF: 2.813.

19. Duprat Neto JP, Mauro AC, Molina AS, Nishinari K, Zurstrassen CE, Costa OF, Belfort FA,

Facure L, Fregnani JH. Isolated limb infusion with hyperthermia and chemotherapy for

advanced limb malignancy: factors influencing toxicity. ANZ J Surg. 2012 Sep 24. [Epub

ahead of print]. IF: 1.248.

20. Duprat Neto JP, Oliveira F, Bertolli E, Molina AS, Nishinari K, Facure L, Fregnani JH.

Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for

regional toxicity. Clinics (Sao Paulo). 2012;67(3):237-41. IF: 2.058.

21. Fanelli MF, Chinen LT, Begnami MD, Costa WL Jr, Fregnami JH, Soares FA, Montagnini

AL. The influence of transforming growth factor-α, cyclooxygenase-2, matrix

metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-

mesenchymal transition on overall survival of patients with gastric cancer. Histopathology.

2012 Aug; 61(2):153-61. IF: 3.082.

22. Fregnani JH, Scapulatempo C, Haikel Jr RL, Saccheto T, Campacci N, Mauad EC, Longatto

Filho A. Could Alarmingly High Rates of Negative Diagnoses in Remote Rural Areas Be

Minimized with Liquid-Based Cytology? Preliminary Results from the RODEO Study Team.

Acta Cytologica. 2012 Dec. 6; 57(1):69-74. IF: 0,488.

23. Haikel RL Jr, Mauad EC, Silva TB, Mattos JS, Chala LF, Longatto Filho A, Barros N.

Mammography-based screening program: preliminary results from a first 2-year round in a

Brazilian region using mobile and fixed units. BMC Womens Health. 2012 Oct 2; 12(1):32. IF:

1.28.


24. Hennes E, Zahn S, Lopes LF, Schomberger S, Leuschner I, Gobel U, Calaminus G,

Schneider DT. Molecular Genetic Analysis of Bilateral Ovarian Germ Cell Tumors. Clin

Pediatrics 2012 Oct; 224(6):359-365. IF: 1.151.

25. Kowalski LP, Sanabria A, Vartanian JG, Lima RA, Mendonca UBT, Santos CR, Boldrini D,

Mello LE, Pinto FP, Lehn CN, Correa LAC, Dedivitis RA, Guimarães AV, Pedruzzi PAG, Ramos

GHA, Gonçalves AJ, Suehara AB, Kanda JL, Capuzzo RC, Oliveira JC, Curado MP, Góis Filho JF,

Fukuyama E, Beserra Júnior I, Carvalho Neto PB, Carvalho AL. Total thyroiDec.tomy with

ultrasonic scalpel: a multicenter, randomized controlled trial. Head and Neck. 2012 Jun;

34(6):805-12. IF: 2.403.

26. Laus AC, Baratela WA, Laureano LA, Santos SA, Huber J, Ramos ES, Rebelo CC, Squire JA,

Martelli L. Karyotype/phenotype correlation in partial trisomies of the long arm of

chromosome 16: Case report and review of literature. Am J Med Genet A. 2012 Apr; 158A

(4):821-7. IF: 2,505.

27. Lima L, Dinis-Ribeiro M, Longatto Filho A, Santos L. Predictive Biomarkers of Bacillus

Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?

Advances in Urology (Print), v. 2012, p. 1-17, 2012. IF: NA.

28. Longatto Filho A, Naud P, Derchain SF, Roteli-Martins C, Tatti S, Hammes LS, Sarian LO,

Eržen M, Branca M, de Matos JC, Gontijo R, Maeda MY, Lima T, Costa S, Syrjänen S, Syrjänen

K. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and

colposcopy in diagnosis of significant cervical pathology. Virchows Archiv. 2012 Jun;

460(6):577-85. IF: 2.491.

29. Longatto Filho A, Villa LL, Syrjänen K. Papillomavirus from the bench to the clinics.

Journal of Oncology. 2012; 2012:437438. IF: NA.

30. Lourenço AV, Fregnani CM, Silva PC, Latorre MR, Fregnani JH. Why are women with

cervical cancer not being diagnosed in preinvasive phase? An analysis of risk factors using a

hierarchical model. Int J Gynecol Cancer. 2012 May;22(4):645-53. IF: 1.646.

31. Marques H, Catarino R, Domingues N, Barros E, Portela C, Almeida MI, Costa S, Reis RM,

Medeiros R, Longatto Filho A. Detection of the Epstein-Barr virus in blood and bone marrow

mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not

associated with prognosis. Oncology Letters, 2012 Dec.;4(6):1285-1289. IF: 0.108.

32. Martino A, Campa D, Buda G, Sainz J, García Sanz R, Jamroziak K, Reis RM, Weinhold N,

Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Stein A, Kumar R, Orciuolo E, Gemignani F,




Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. Polymorphisms in

xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and Multiple Myeloma Risk: a

case-control study in the context of the IMMEnSE (International Multiple Myeloma rESEarch)

consortium. Leukemia, 2012 Jun; 26(6):1419-22. IF: 9.561.

33. Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R,

Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S,

Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Genetics and molecular

epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J

Oncol. 2012 Mar; 40 (3): 625-38. IF: 2.399.

34. Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, García-Sanz R, Lesueur F,

Marques H, Moreno V, Jurado M, Ríos R, Szemraj-Rogucka Z, Szemraj J, Tjønneland A,

Overvad K, Vangsted AJ, Vogel U, Mikala G, Kádár K, Szombath G, Varkonyi J, Orciuolo E,

Dumontet C, Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K, Canzian F.

Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple

myeloma. British Journal of Haematology, 2012 Sep; 158 (6):805-9. IF: 4.941.

35. Martinho O, Falopp C, Scapulatempo Neto C, Longatto Filho A, Baiocchib G, Cunha I,

Soares FA, Fregnanig JH, Reis RM. Loss of RKIP expression during the carcinogenic evolution

of endometrial cancer. Journal of Clinical Pathology, 2012 Feb; 65 (2):122-8. IF: 2.306.

36. Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Gonçalves V, Honavar M, Costa

P, Damasceno M, Rosner MR, Lopes JM, Reis RM. Downregulation of RKIP is associated with

poor outcome and malignant progression in gliomas. PLoS One. 2012; 7(1):e30769. IF: 4.092.

37. Martins TG, Trigo G, Fraga AG, Gama JB, Longatto Filho A, Saraiva M, Silva MT, Castro

AG, Pedrosa J. Corticosteroid-Induced Immunosuppression Ultimately Does Not

Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection.

PLoS Neglected Tropical Diseases. 2012 Nov; 6(11):e1925. IF: 4.716.

38. Oliveira AT, Pinheiro C, Longatto Filho A, Scapulatempo C, Matos D, Martinho O,

Vazquez VL, Carvalho AL, Saad SS, Brito MJ, Silva TB, Reis RM, Baltazar F. Co-expression of

monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low

survival in patients with gastrointestinal stromal tumors (GISTs). Journal of Bioenergetics

and Biomembranes, v.44, p. 171-178, 2012. IF: 2.813.

http://lattes.cnpq.br/7827758855739399


39. Oliveira DT, Biassi TP, Faustino SE, Carvalho AL, Landman G, Kowalski LP. Eosinophils

may predict occult lymph node metastasis in early oral cancer. Clin Oral Investig, 2012 Dec.;

16(6):1523-8. IF: 2.364.

40. Oliveira RDR, Fontana V, Junta CM, Marques MM, Macedo C, Rassi DM, Passos GAS,

Donadi EA, Louzada Jr, P. Differential gene expression profiles may differentiate responder

and non-responder rheumatoid arthritis patients for methotrexate monotherapy and

methotrexate plus TNF-blocker combined therapy. The Journal of Rheumatology, 2012, Aug

39(8); 1524-32. IF: 2, 91.

41. Pinheiro C, Longatto Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of

monocarboxylate transporters in human cancers: state of the art. Journal of Bioenergy and

Biomembrane. 2012 Feb; 44(1):127-39. IF: 2.813.

42. Pinheiro C, Longatto Filho A, Nogueira R, Schmitt F, Baltazar F. Lactate-induced IL-8

pathway in endothelial cells--letter. Cancer Research. 2012 Apr 1; 72(7):1901-2 IF: 7.856.

43. Pinheiro C, Longatto Filho A, Soares TR, Pereira H, Bedrossian C, Michael C, Schmitt FC,

Baltazar F. CD147 immunohistochemistry discriminates between reactive mesothelial cells

and malignant mesothelioma. Diagnostic Cytopathology. 2012 Jun; 40(6):478-83 IF: 1.160.

44. Santos EMM, Dominguez-Valentin M, Carneiro F, Oliveira LP, Ferreira FO, Nakagawa W

T, Gomy I, Ferraz VEF, Silva WA, Carraro DM, Rossi BM. Predictive models for mutations in

mismatch repair genes: implication for genetic counseling in developing countries. BMC

Cancer (Online) 2012 v. 12, p. 64-64. IF: 3.01.

45. Silva-Correia J, Miranda-Gonçalves V, Salgado AJ, Sousa N, Oliveira JM, Reis RM, Reis RL.

Angiogenic potential of gellan gum-based hydrogels for application in nucleus pulposus

regeneration: In vivo study. Tissue Eng Part A, 2012 Jun; 18 (11-12):1203-12.IF: 4.022.

(Journal cover).

46. Silveira VS, Canalle R, Scrideli CA, Queiroz RG, Lopes LF, Tone LG. CYP3A5 and NAT2

gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment

outcome. Molecular and Cellular Biochemistry, v. 364, p. 217-223, 2012. IF: 2,057.

47. Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto Filho A, Derchain S, Kozachenko V,

Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M,

Grunjberga V, Erzen M, Juschenko A, Serpa Hammes L, Podistov J, Costa S, Syrjänen S; NIS

Study Research Group; LAMS Study Research Group. Covariates of high-risk human





papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by

competing-risks regression models. Eur J Gynaecol Oncol. 2012; 33(1):5-14. IF: 0.474.

48. Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto Filho A, Derchain S, Kozachenko V,

Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M,

Grunjberga V, Erzen M, Juschenko A, Hammes LS, Podistov J, Costa S, Syrjänen S; NIS Study

Research Group; LAMS Study Research Group. Longitudinal outcomes of high-risk human

papillomavirus (HPV) infections as competing-risks events following cervical HPV test at

baseline visit in the NIS-LAMS cohort. Eur J Gynaecol Oncol. 2012; 33(4):341-52. IF: 0,474.

49. Tiburcio M, Costa SM, DE Fatima Duarte M, Schmitt FC, Longatto Filho A.

Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic

significance. Oncology Letters. 2012 Oct; 4(4):647-657. IF: 0.108.

50. Torrezan GT, Carneiro da Silva FC, Monteiro dos Santos EM, Rossi BM, Carraro DM,

Krepischi ACV. A novel SYBR-based duplex qPCR for the detection of gene dosage: detection

of an APC large deletion in a familial adenomatous polyposis patient with an unusual

phenotype. BMC Medical Genetics (Online). 2012 v. 13, p. 55-69. IF: 2.33.

51. Valadao M, Braggio D, Santos AF, Linhares E, Goncalves R, Romano S, Vilhena B, Small I,

de Oliveira, AT, Martinho, O, Reis, RM, Guimarães, DP, Ferreira, CG. Involvement of signaling

molecules in the prediction of response to imatinib treatment in metastatic GIST patients.

Journal of Surgical Research, 2012 Nov; 178(1):288-93. IF: 2.247.

52. Valentin MD, Da Silva FC, Santos EM, Da Silva SD, De Oliveira Ferreira F, Aguiar Junior S,

Gomy I, Vaccaro C, Redal MA, Della Valle A, Sarroca C, Rasmussen LJ, Carraro DM, Rossi BM.

Evaluation of MLH1 I219V polymorphism in unrelated South American individuals suspected

of having Lynch syndrome. Anticancer Research. 2012 Oct; 32(10):4347-51. IF: 1.65.

4.3) Publications in Brazilian Journals

1. Giacomazzi J, Aguiar E, Palmero EI, Schmidt AV, Skonieski G, Duarte-Filho D, Bock H,

Saraiva-Pereira ML, Ewald IP, Schuler-Faccini L, Camey SA, Caleffi M, Giugliani R, Ashton-

Prolla P. Prevalence of ER -397 PvuII C/T, ER -351 XbaI A/G and PGR PROGINS

polymorphisms in Brazilian breast cancer unaffected women. Brazilian Journal of Medical

and Biological Research. 2012, Oct; 45(10):891-7. IF: 1.150.




2. Gurgel JD, Pereira CS, Fregnani JH, Ribeiro F de A. Method for removal of samples of ear

canal and tympanic membrane for histologic and immunhistochemical study. Braz J

Otorhinolaryngol. 2012 Feb; 78(1):37-42.

3. Liberman PHP, Goffi-Gomez MV, Schultz C, Lopes LF. Quais as frequências audiométricas

acometidas são responsáveis pela queixa auditiva nas disacusias por ototoxicidade após o

tratamento oncológico? Arquivos internacionais de otorrinolaringologia. 2012, 16, 26-31.

4. Matthes AG, Vieira R, Bailão A, Watanabe, A Kerr L, Saculatempo-Neto C, Uemura G,

Folgueira M. The role of tumor marking techniques in the treatment of locally advanced

breast cancer. Revista Brazileira de Mastologia. 2012, 21, 140-146.

5) Conferences and Congresses

5.1) Oral Communications

1. Arantes LMRB, Carvalho AC, Tajara EH, Carvalho AL, Bertollo EMG. Methylation profile of

CCNA1, p16, HIC1, TIMP3, MGMT and DCC genes in head and neck cancer. In: 16th

International Congress on Oral Pathology and Medicine and 20th Brazilian Congress of Oral

Medicine and Pathology, São Pedro, Brazil.

2. Bravo-Calderón DM, Lauand GA, Nonogaki S, Carvalho AL, Kovalski LP, Marana, AN.

Oliveira DT. BETA-2 adrenergic receptor expression in surgical margins of oral squamous cell

carcinoma. In: 16th International Congress on Oral Pathology and Medicine and 20th

Brazilian Congress of Oral Medicine and Pathology, São Pedro, Brazil

3. Campacci N, Fonseca TCB, Michelli RD, Haikel Junior R, Mauad EC, Reis RM, Carvalho AL,

Viana DV, Palmero EI. “Utilizaçao das unidades moveis e fixa de prevençao para

rastreamento populacional de familias com predisposiçao hereditaria de cancer de mama

e/ou colorretal”. III Encontro Científico do Hospital de Câncer de Barretos, 7 de January,

2012, Barretos, São Paulo, Brazil.

4. Carvalho AL, Mohssen A. Chiesa F, Kowalski LP. In the Era of Organ Preservation, What is

the Role of cT3 Laryngeal Surgery?. In: 8th International Conference on Head and Neck

Cancer, Toronto, Canada.

5. Carvalho AC, Maia DCC, Carvalho AL, Scapulatempo-Neto C, Vettore AL. MicroRNAs as

diagnostic markers for lymph node metastasis in OSCC. In: 16th International Congress on

Oral Pathology and Medicine and 20th Brazilian Congress of Oral Medicine and Pathology,

São Pedro, Brazil.










6. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira HCS. Assessing the

genotoxicity of urban air quality in Barretos during the sugarcane burning using Tradescantia

micronucleus (Trad-MCN) bioassay. In: 58 Congresso Brazileiro de Genética, 2012,

September de 2012, Foz do Iguaçu PR, Brazil.

7. de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J,

Oliveira P, Hespanhol V, Reis RM. Association between EGF +61 genetic polymorphisms and

non-small cell lung cancer increased risk in a Portuguese population: a case-control study.

Spring Meeting Oncology 2012. Évora, Portugal.

8. de Mello RA, Ferreira M, Pires FS, Costa C, Luis M, Cunha J, Oliveira P, Hespanhol V, Reis

RM. The role of genetic polymorphisms at the chromosomes 5p15.33, 6p12, 6p21, 6p21.3,

and 15q25 into non-small-cell lung cancer prognosis: a Portuguese prospective study. São

Paulo Advanced School of Comparative Oncology 30 Sept 30 – October 7, 2012. Águas de

São Pedro, SP, Brazil.

9. Hatakeyama M, Reis-Rosa L A, Abreu FB, Marchi FA, Spilborghs G, Carvalho AL, Nicolau U

R, Kowalski LP, Rogatto SR. Molecular Biomarkers of Chemo-Radiotherapy Response in

Oropharyngeal Squamous Cell Carcinomas. In: 8th International Conference on Head and

Neck Cancer, Toronto, Canada.

10. Laus AC, Santos SA, Laureano LAF, Huber J, Squire JA, Martelli L. Molecular Cytogenetic

Characterization of Supernumerary Marker Chromosomes. Encontro Paulista de

Citogenética, 2012, Ribeirão Preto, SP, Brazil.

11. Lopes LF- Papel do PET-CT nos TCG0 tumores de celulas germinativas na infancia. XIII

Congresso Brazileiro de Oncologia Pediatrica, 17-20 April, 2012, Natal, Brazil.

12. Marino ALF, Macedo T, Longatto Filho AF, Kerr LM, Vieira RAC, Evangelista AF, Silveira

HCS, Marques MMC. 58 Congresso Brazileiro de Genética-Prêmio Francisco Mauro Salzano,

September 11-14, 2012, Foz do Iguaçu, PR, Brazil.

13. Martinho O, Oliveira RJS, Miranda-Gonçalves V, Clara C, Almeida JR, Carvalho AL, Reis

RM. “Terapia molecular dirigia com cediranib, sunitinib e imatinib em modelos in vitro de

glioblastoma”. III Encontro Científico do Hospital de Câncer de Barretos, January7º, 2012,

Barretos, São Paulo, Brazil.

14. Martinho O, Pinto F, Granja S, Miranda-Gonçalves V, Moreira M, Ribeiro L, di Loreto C,

Rosner M, Longatto Filho A, Reis RM. Raf Kinase inhibitor (RKIP) depletion is associated with

cervical cancer aggressiveness. 10th ICCB/16th SBBC Meeting, July, 25-28, 2012, Rio de




Janeiro, Brazil.

15. Silva-Correia J, Pereira H, Yan L-P, Miranda-Gonçalves V, Oliveira A.L, Oliveira J.M, Reis

RM, Espregueira-Mendes JD, Reis RL. (2012). Novas matrizes de seda para Engenharia de

Tecidos do Menisco: A importância do controlo da neovascularização com Hidrogéis de

Goma Gelana Metacrilada – XXXII Congress of the Portuguese Society of Orthopaedics and

Traumatology, Vilamoura, Portugal.

5.2) Posters

1. Almeida MI, Nicoloso M, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Bondaruk J, Fabbri M,

Czerniak B, Lanza G, Reis RM, Zweidler-McKay P, Calin GA. Strand-Specific miR-28-5p and

miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. São Paulo Advanced School of

Comparative Oncology (ESPCA), September,30 to October 6, 2012, São Paulo, Brazil.

2. Ashton-Prolla P, Osorio CABT, Koehler-Santos P, Graudenz MS, Palmero EI, Fernandes G,

Michelli RD et al. Contribution of TP53 p.R337H mutation to breast cancer prevalence in

Brazil. In: 2012 ASCO Annual Meeting. June 1st to -5th, 2012, Chicago, USA.

3. Campacci N, Ramadan L, Caron TB, Fonseca TCB, Mauad EC, Michelli RD, Viana DV,

Palmero EI. Identification of at-risk families for hereditary breast cancer through a Brazilian

Cancer Prevention Network in a population-based sample. In: 4th International Symposium

on Hereditary Breast and Ovarian Cancer: From Theory to Practice. April, 25to27, 2012 ,

Montreal, Canada.

4. Campacci N, Ramadan L, Mauad EC, Michelli RD, Viana DV, de Oliveira JC, Lima MP, de

Lima JC, Andrade C, Palmero EI. Is there a place for oncogenetics inside the Prevention Unit?

In: 4th International Symposium on Hereditary Breast and Ovarian Cancer: From Theory to

Practice. April 25to27, Montreal, Canada.

5. Campacci N, de Lima JO, Ramadam L, Michelli RD, Viana DV, Reis RM, Rossi BM, Mauad

EC, Carvalho AL, Palmero EI. Identificação de famílias em risco para câncer de mama e

câncer colorretal hereditários em uma amostra de base populacional. IV Encontro Cientifico

do Hospital de Câncer de Barretos, December, 2012, Barretos, SP, Brazil.

6. Campanella NC, Scapulatempo-Neto C, de Oliveira A.T, Guimaraes DP, Reis RM. Study of

microsatellite instability and potential target genes in GISTs. VII Congresso Franco Brazileiro

de Oncologia, September, 20to22, 2012, Rio de Janeiro, Brazil.


7. Camparoto ML, Scapulatempo-Neto C, Squire JA. Evaluation of HER-2 IHC and FISH

Analysis in Breast Cancer at the Routine Pathology of the Barretos Cancer Hospital-SP, Brazil.

Encontro Paulista de Citogenética, April, 22 to 24 of 2012, Ribeirão Preto, Brazil.

8. Carloni AC, Oliveira RJS, Camparotto ML, Clara C, Squire JA, Reis RM. Estabelecimento e

Caracterização Citogenética e Molecular de Culturas Primárias de Gliomas – Ensaios

Preliminares. II Encontro Paulista de CitogenéticaApril, 22 to 24, 2012, Ribeirão Preto, Brazil.

9. Carvalho D, Bjerke L, Bax D, Chen L, Kozarewa I, Baker S, Grundy R, Ashworth A, Lord C,

Hargrave D, Reis RM, Jones C. Identification of novel fusion genes in paediatric high grade

glioma. 15th International Symposium on Pediatric Neuro-Oncology – ISPNO, June, 24to27,

2012, Toronto, Canada.

10. Carvalho AL, Agra IMG, Scapulatempo Neto C, Kovalski LP. Locally Recurrent Oral

Carcinomas Submitted to Salvage Surgery: Expression of EGFR and p16 and their Relation

with the Treatment Outcomes. In: 8th International Conference on Head and Neck Cancer,

Toronto, Canada.

11. Carvalho GB, Gonçalves Filho J, Lima SP, Mannarini L, Horst MA, Carvalho AC, Maia DCC,

Carlin V, Carvalho AL, Kowalski LP, Vettore AL. MicroRNAs Profiling in Salivary Rinse from

Patients with Head and Neck Squamous Cells Carcinoma. In: AACR Annual Meeting, Chicago,

USA.

12. Carvalho GB, Gonçalves Filho J, Lima SP, Carvalho AL, Mohssem A, Chiesa F, Patel SG,

Montero PH, Shuman AG, Shah JP, Kowalski LP. Results of Treatment of T4A Squamous Cell

Carcinoma of the Larynx. In: 8th International Conference on Head and Neck Cancer,

Toronto, Canada.

13. Carvalho GB, Gonçalves Filho J, Lima SP, Carvalho AL, Mohssen A, Chiesa F, Patel SG,

Shaah JP, Kowalski LP. Predictive Factors of Prolonged Hospital Stay in Patients Undergoing

Total Laryngectomy. In: 8th International Conference on Head and Neck Cancer, Toronto,

Canada.

14. Colaiacovo W, Guimaraes DP, Gilberto Fava, Aldenir Fresca, Liza Alvarenga, Thiago R. Da

Cunha, Emiliano D. Almodova. Self-Expanding Metal Stent (SEMS) for Malignant Colorectal

Obstruction (MCO). Gastrointestinal Endoscopy Vol. 75, Issue 4, Supplement, Page AB427,

DDW, May, 19to22, Chicago, USA.

15. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira HCS. Assessing

the genotoxicity of urban air quality in Barretos during the sugarcane burning using













Tradescantia micronucleus (Trad-MCN) bioassay. 58 Congresso Brazileiro de Genética, 2012,

September, 2012, Foz do Iguaçu PR, Brazil.

16. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira HCS. Assessing


Tradescantia micronucleus (Trad-MCN) bioassay. IV Encontro Científico do Hospital de

Câncer de Barretos, December, 2012, Barretos, SP, Brazil.

17. de Mello RA, Ferreira F, Pires FS, Costa S, Luis M, Cunha J, Oliveira P, Hespanhol V, Reis

RM. The role of genetic polymorphisms in the chromosomes 5p15.33, 6p12, 6p21, 6p21.3,

and 15q25 into non-small-cell lung cancer prognosis: a Portuguese prospective study. São

Paulo Advanced School of Comparative Oncology (ESPCA), September 30th to October 6th,

2012, São Paulo, Brazil.

18. da Silva TR, de Oliveira JC, Rossi BM, Palmero EI. Identificação e caracterização de

pacientes em risco para câncer colorretal hereditário. IV Encontro Cientifico do Hospital de

Câncer de Barretos, December, 2012, Barretos, SP, Brazil.

19. de Lima JO, Campacci N, Ramadan L, Palmero EI. Utilização de um guia informativo para

avaliar o conhecimento em relação ao Câncer Hereditário. IV Encontro Cientifico do Hospital

de Câncer de Barretos, December 2012, Barretos, SP, Brazil.

20. dos Santos LC, Nogueira de Souza N, Scapulatempo-Neto c, Berardinelli G, dos Santos FP,

Lopes H, Silva MC, Jácome A, Oliveira J, Denadai M, Carvalho AL, Reis RM. Study of

Biomarkers Predictive of Response to Anti-EGFR Monoclonal Antibodies for Metastatic

Colorectal Cancer Patients: The experience of Barretos Cancer Hospital. Global Academic

Program Meeting, May 14th to16th 2012, Oslo, Norway.

21. Evangelista, AF; Xavier DJ; Sakamoto-Hojo ET; Donadi EA; Passos GAS; Marques MMC.

MicroRNAs from peripheral blood mononuclear cells can be used as biomarkers for

detection of preclinical fibrosarcoma. Hallmarks of Cancer, October 29 th to31st, San

Francisco-CA, USA.

22. Fernandes GC, Fonseca TCB, Michelli RAD, Mendes DRP, Escremin AP, Reis RM, Viana DV,

Mauad EC, Scapulatempo-Neto C, Palmero EI. Prevalence of positive breast cancer history

and triple negative breast cancer cases in women with and without BRCA germline

mutations. In: 58 Congresso Brazileiro de Genética, 2012, Foz do Iguaçu PR, Brazil.

23. Fernandes GC, Fonseca TCB, Michelli RD, de Paula DR, de Paula AE, Viana DV,

Scapulatempo-Neto C, Palmero EI. Triple Negative breast cancers and positive family history


are predictors of BRCA1 germline mutations. IV Encontro Cientifico do Hospital de Câncer de

Barretos, December 2012, Barretos, SP, Brazil.

24. Hennessey PT, Mydlarz WK, Wang H, Carvalho AL, Califano JA. Serum Biomarkers for

Detection of Head and Neck Squamous Cell Carcinoma. In: 8th International Conference on

Head and Neck Cancer, Toronto, Canada.

25. Horst MA, Carvalho AC, Maia DC, Pelarin MFA, Carvalho AL, Kowalski LP, Vettore AL.

MicroRNAs in salivary rinse as biomarkers for recurrence detection of head and neck

squamous cell carcinoma. In: 16th International Congress on Oral Pathology and Medicine

and 20th Brazilian Congress of Oral Medicine and Pathology, 2012, São Pedro. Scientific

Program, 2012.

26. Lacerda C, Campanella NC, Scapulatempo-Neto C, Wohnrath DR, Almodova E, Silva S,

Dias C, Oliveira AT, Guimaraes DP, Reis RM. Esophageal GIST: a case report. 11th OESO

World Congress on Diseases of the Oesophagus. September 01st to 04th, 2012, Como, Italy.

27. Lacerda C, Carloni AC, Scapulatempo-Neto C, Crema E, Rodrigues MA, de Oliveira AT,

Guimaraes DP, Reis RM. TP53 gene mutations in Squamous Cells Carcinoma of the

Esophagus Associated with Chagasic Megaesophagus. 11th OESO World Congress on

Diseases of the Oesophagus. September 01-04, 2012, Como, Italy.

28. Laus AC, Santos SA, Laureano LAF, Huber J, Squire JA, Martelli L. Molecular Cytogenetic

Characterization of Supernumerary Marker Chromosomes. Encontro Paulista de

Citogenética, 2012, Ribeirão Preto, SP, Brazil.

29. Laus AC, Macedo T, Carvalho AC, Scapulatempo Neto C, Carvalho AL, Palmero EI,

Marques MMC. MicroRNAs contribute to the chemoresistance of cisplatin and paclitaxel in

patients with head and neck squamous cell carcinoma. 3° Encontro Científico do Hospital de

Câncer de Barretos, 2012, Barretos, SP, Brazil.

30. Lopes LF, Gaiolla RD, Niero-Melo L, Lorand-Metze I, Velloso EDRP, Tanizawa RSS,

Campanaro CM, Souto EX, Zerbini MC, Luporini SM, Lee ML, Magalhães IMQS, Pinheiro VR,

Seber A, Vidal DO, Santos VR. The Brazilian Cooperative Group on Pediatric Myelodysplastic

Syndrome (GCB-SMD-PED). Is it relevant to improve educational approach and correct

diagnosis? VI International Symposium on Myelodysplastic Syndromes and Bone Marrow

Failures in Childhood. November 7th to9th, 2012, Prague, Czech Republic.

31. Macedo T; Evangelista AF; Kerr LM; Guerreiro da Silva IDC; Vieira RAC; Marques MM

Differential expression of circulating microRNAs in serum of breast cancer patients using





quantitative reverse transcription (qRT-PCR). VII Congresso Franco Brazileiro de Oncologia,

September, 20th to 22nd, Rio de Janeiro, Brazil.

32. Macedo T; Laus C; De Carvalho AC; Queiroz Junior AF; Kerr LM; Marino ALF; Rodriges AL;

Guerreiro da Silva IDC; Vieira RAC; Marques MMC. Circulating microRNAs are differentially

expressed in the serum of patients with breast câncer. 3° Encontro Científico do Hospital de

Câncer de Barretos, 2012, Barretos, SP, Brazil.

33. Marino ALF; Macedo T; Queiroz Junior AF; Kerr LM; Vieira RAC; Evangelista AF; Silveira

HCS; Marques MMC. Analysis of microRNA expression comparing matched frozen and

formalin-fixed paraffin- embedded human breast cancer samples. 3° Encontro Científico do

Hospital de Câncer de Barretos, 2012, Barretos, SP, Brazil.

34. Marino ALF; Macedo T; Queiroz Junior AF; Kerr LM; Vieira RAC; Evangelista AF; Silveira

HCS; Marques MMC. Analysis of microRNA expression usisng tissue frozen and formalin-

fixed paraffin embedded from breast cancer samples. MicroRNA 2012 International

Symposium, 2012, São Paulo, Brazil.

35. Marino ALF; Evangelista AF; Longatto Filho A; Kerr LM; Vieira RAC; Macedo T; Silveira

HCS; Marques MMC. Differential expression profile of microRNAs during human breast

cancer progression. 58° Congresso Brazileiro de Genetica, September 11th to14th, Foz do

Iguaçu, PR, Brazil.


HCS; Marques MMC. Differential expression profile of microRNAs during human breast

cancer progression. VII Congresso Franco Brazileiro de Oncologia, September, 20th to 22nd,

Rio de Janeiro, Brazil.


HCS; Marques MMC. Differential expression profile of paraffin embedded microRNAs during

human breast cancer progression. Hallmarks of Cancer, October 29th to 31st, San Francisco-

CA, USA.

38. Martinho O, Miranda-Gonçalves V, Reis RM. Identification of novel potential predictive

targets to anti-angiogenic therapy response in glioblastomas. 10th ICCB/16th SBBC Meeting,

July 25th to 28th, 2012, Rio de Janeiro, Brazil.

39. Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R,

Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S,

Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Comprehensive investigation of the


8q24 region and multiple myeloma risk in the context of the IMMENSE Consortium. 17th

EHA congress, 14th to 17th June 2012, Amsterdam, Holland.

40. Mendes DRP, Fernandes GC, Escremin AP, Michelli RAD, Andrade CE, Oliveira JC, Mauad

EC, Reis RM, Viana DV, Palmero EI. High frequency of a BRCA1 founder mutation in a non-

Jewish population affected by bilateral breast cancer. In: 58 Congresso Brazileiro de

Genética, 2012, Foz do Iguaçu PR, Brazil.

41. Miranda-Gonçalves V, Honavar M, Pinheiro C, Reis RM, Baltazar F. MCT1 plasma

membrane expression is associated to hypoxic regions in glioblastomas. EACR22, 7 to 10 July

2012, Barcelona, Spain.

42. Motta VM, Camparoto ML, Ferreira MCS, Gonçalves IZ, Paton, EJA, Castro NS , Colli GF,

Squire JA. Retrospective cytogenetic approach on patients with hematological malignancies

at Barretos Cancer Hospital. Encontro Paulista de Citogenética, 22nd to 24th, April, 2012,

Ribeirão Preto, SP, Brazil.

43. Nandhabalan M, Bjerke L, Bax DA, Carvalho D, Bajrami I, Ashworth A, Lord C, Reis RM,

Workman P, Jones C. H3F3A mutations in paediatric glioblastoma regulate a self-renewal

gene signature. 15th International Symposium on Pediatric Neuro-Oncology – ISPNO, June,

24th to 27th, 2012, Toronto, Canada.

44. Oliveira RS, Martinho O, Clara C, Almeida JR, Reis RM. Establishment of primary

glioblastoma cell cultures for new treatment approaches screening. 10th ICCB/16th SBBC

Meeting, July 25th to 28th, 2012, Rio de Jananeiro, Brazil.

45. Palmero EI, Michelli RD, Rossi BM, de Oliveira JC, Andrade C, Lima MP, de Lima JC,

Mauad E, Reis RM, Carvalho AL, Viana DV. Free of cost genetic counseling of at-risk for

hereditary breast and ovarian cancer families from Brazilian Federal Health Insurance: A

pioneer institutional experience. In: 4th International Symposium on Hereditary Breast and

Ovarian Cancer: From Theory to Practice. April 25 th to -27 th, 2012, Montreal, Canada.

46. Pinto F, Martinho O, Moniz S, Jones C, Lopes JM, Honavar M, Pires MM, Jordan P, Reis

RM. Protein kinase WNK2 was correlated with poor outcome and malignant behavior in

glioma cell lines. EACR22, 7 to 10 July 2012, Barcelona, Spain.

47. Pinto F, Andrade RP, Reis RM. T-box transcription factor Brachyury as a suppressor gene

in gliomas? São Paulo Advanced School of Comparative Oncology (ESPCA), September30th

to 6th October 2012, São Paulo, Brazil.


48. Rossi BM, Michelli RD, Viana DV, de Oliveira JC, Andrade C, Reis RM, de Paula DR,

Fernandes G, Carvalho AL, Palmero EI. Free of cost genetic counseling and testing of at-risk

for hereditary cancer families from Brazilian Federal Health Insurance: A pioneer

institutional experience. In: Society of Surgical Oncology’s 65th Annual Cancer Symposium.

March 21st-24th, Orlando, EUA.

49. Silva AG, Maschietto M, Vidal DO, Peliçario LM, Velloso EDRP, Lopes LF, Krepischi AC,

Rosenberg C. Array-CGH as an adjuvant tool in cytogenetic diagnosis of myeloid neoplasms.

VI International Symposium on Myelodysplastic Syndromes and Bone Marrow Failures in

Childhood. November 7th to 9th, 2012, Prague, Szech Republic.

50. Silva DS, Viana-Pereira M, Stavale JN, Malheiro S, Almeida GS, Clara C, Jones C, Reis RM.

Study of MSI and novel target genes associated with MSI phenotype in medulloblastomas.

15th International Symposium on Pediatric Neuro-Oncology – ISPNO, 24th to 27th, June

2012, Toronto, Canada.

51. Silveira HCS, Schmidt-Carrijo M, Zanardo-Oliveira C, Seidel EH, Villegas C, Scapulatempo

C, Longatto Filho A, Carvalho AL, Reis RM, Saldiva PH. Análise da Poluição do Ar gerada pela

queima da palha da cana-de-açúcar e suas relações com a mutagênese humana. III Encontro

Cientifico do Hospital de Câncer de Barretos, 6th to 7th, January, 2012, Barretos, SP, Brazil.


C, Longatto Filho A, Carvalho AL, Reis RM, Saldiva PH. Evaluation of genotoxic effects of

sugarcane workers using micronucleus assay. In: 58 Congresso Brazileiro de Genética, 2012,

Foz do Iguaçu PR, Brazil.


C, Longatto Filho A, Carvalho AL, Reis RM, Saldiva PH. Evaluation of genotoxic effects of

sugarcane workers using micronucleus assay. IV Encontro Científico do Hospital de Câncer

de Barretos, December 2012, Barretos, SP, Brazil.

54. Velloso EDRP, Chauffaille ML, Peliçario LM, Tanizawa RSS, Toledo SRC, Gaiolla RD, Vidal

DO, Lopes LF. Cytogenetics from the Brazilian MDS Pediatric Group (GCB-SMD-PED). VI

International Symposium on Myelodysplastic Syndromes and Bone Marrow Failures in

Childhood. November 7th to 9th 2012, Prague, Szech Republic

55. Viana-Pereira M, Pereira MS, Burford A, Jury A, Popov S, Perryman L, Bax DA, Forshew T,

Sheer D, Pimentel J, Pires M, Reis RM, Jones C. Molecular determinants of efficacy of MET










receptor inhibition in paediatric glioblastoma. 15th International Symposium on Pediatric

Neuro-Oncology – ISPNO, 24th to 27th, June 2012, Toronto, Canada.

56. Viana-Pereira M, Pereira MS, Burford A, Jury A, Popov S, Perryman L, Bax DA, Forshew T,

Tatevossian R, Sheer D, Pimentel J, Pires MM, Reis RM, Jones C. Molecular study and

inhibition of MET receptor in paediatric high-grade glioma. São Paulo Advanced School of

Comparative Oncology (ESPCA), September 30th -6th October 2012, São Paulo, Brazil.

57. Vieira de Castro J, Martinho O, Miranda-Gonçalves V, Baltazar F, Reis RM. Dissecting the

role of glioblastoma cell metabolism in response to imatinib. Porto Cancer Meeting, 19th

20th April 2012, Porto, Portugal.

58. Vieira de Castro J, Martinho O, Miranda-Gonçalves V, Baltazar F, Reis RM. Role of

glioblastoma cell metabolism in response to anti-RTK therapy. EACR22, 7th to 10th July 2012,

Barcelona, Spain.

59. Vidal DO, Silva AG, Marchietto M, Vieira H, Lopes LF, Brentani H, Rosenberg C, Krepischi

AC. Microarray-Based DNA methylation analysis in pediatric myelodysplastic syndrome and

juvenile myelomonocytic leukemia. VI International Symposium on Myelodysplastic

Syndromes and Bone Marrow Failures in Childhood. November 7th 9th 2012, Szech Republic.

60. Yamane L, Scapulatempo Neto C, Alvarenga L, Oliveira C, Berardinelli G, Almodova E,

Cunha TR, Colaiacovo W, Melani A, Freganini JH, Reis RM, Guimarães DP. Morphological and

molecular characterization of colorectal lesions detected and removed by colonoscopy.

Global Academic Program Meeting, May 14 th16th 2012, Oslo, Norway

61. Yamane L, Scapulatempo Neto C, Alvarenga L, Zanardo, C, Berardinelli G, Almodova E,

Cunha TR, Colaiacovo W, Melani A, Freganini JH, Reis RM, Guimarães DP. Study of the

morphologic and molecular profile of colorectal lesions detected and removed by

colonoscopy. VII Congresso Franco Brazileiro de Oncologia, September, 20th to 22nd, Rio de

January, Brazil.

6) Science Communication to general public

-Silveira HCS: Fumaça gerada pela queima do diesel causa câncer, alerta OMS. Gazeta do

Povo,Curitiba,16deJuly2012.

(http://www.gazetadopovo.com.br/vidaecidadania/conteudo.phtml?tl=1&id=1274792&tit=

Fumaca-gerada-pela-queima-do-diesel-causa-cancer-alerta-OMS).

http://www.gazetadopovo.com.br/vidaecidadania/conteudo.phtml?tl=1&id=1274792&tit=Fumaca-gerada-pela-queima-do-diesel-causa-cancer-alerta-OMS

http://www.gazetadopovo.com.br/vidaecidadania/conteudo.phtml?tl=1&id=1274792&tit=Fumaca-gerada-pela-queima-do-diesel-causa-cancer-alerta-OMS


-Reis RM, Carvalho AL: Revista Hospital do Futuro, HdF Nº15, Portugal – O Hospital de

Câncer de Barretos.

7) Supervision of PhD, Master and Trainee Fellows

7.1) PhD Thesis

1. Adriana Lorenzi. “Valor do teste careHPV de captura híbrida em Unidade Móvel no

rastreio do câncer cervical em áreas rurais e remotas”. HCB (Supervisor - Longatto Filho, A.).

2011 to present.

2. Aline Nazareth de Paiva Paixão Becker. “Avaliação da via MAPK na oncogênese dos

astrocitomas pilocíticos”. HCB (Supervisor – Reis RM; Co-supervisor – Scapulatempo-Neto C).

2012 to present.

3. Carolina Dias Carlos. “Estudo de Biomarcadores Terapêuticos em pacientes com Câncer

de Pulmão do Hospital de Câncer de Barretos”. HCB (Supervisor – Reis RM; Co-supervisor –

Scapulatempo-Neto C; Co-supervisor – Viana L). 2012 to present.

4. Filipe Pinto, projeto “Learning from the embryo: Understanding early embryonic T gene -

Brachyury - impact in human tumorigenesis” ICVS, Universidade do Minho (Supervisor – Reis

RM). 2011 to present.

5. Herlander Jose Resende Marques. Prevalência de vírus Herpes nos Linfomas Foliculares

Influência dos polimorfismos dos sistemas apresentadores de antigénio na infecção crónica.

ICVS, Universidade do Minho. (Supervisor - Longatto Filho A). 2008 to present.

6. Julieta Alexandra Pereira Afonso. The Biology of Lymphatic Spread of Urothelial Bladder

Cancer. ICVS, Universidade do Minho. (Supervisor - Longatto Filho A). 2008 to present.

7. Junea Caris de Oliveira. “Correlação genotipo-fenotipo em pacientes portadores de

Polipose Adenomatosa Familial”. HCB (Supervisor – Rossi BM; Co-Supervisor Palmero EI).

2012 to present.

8. Leonado Gabeira Secco. “Fatores Prognósticos em Carcinoma Bem Diferenciado da

Tireóide”. FMUSP (Supervisor – Carvalho AL). 2005 to present.

9. Maria Inês Almeida, projeto “Molecular determinants of human susceptibility to solid

tumors and therapy response: A microRNA Hub” ICVS Universidade do Minho/MD Anderson,

Houston, USA (Supervisor – Reis RM). 2009 to 2012.


10. Maria Teresa Roncaglia, projeto “O valor da captura híbrida para HPV no seguimento de

pacientes com neoplasia intra-epitelial de alto grau submetidas à conização do colo uterino

por cirurgia de alta freqüência”. FMUSP (Supervisor – Longatto Filho A). 2010 to present.

11. Roberta Targa Stramandinoli, projeto “Avaliação da interface osso/implante em

mandíbula de miniporcos irradiados e o uso de biomateriais na osseointegração”. FMUSP

(Supervisor – Carvalho AL). 2010 to present.

12. Sandra Fátima Fernandes Martins. ICVS, Universidade do Minho. (Supervisor - Longatto

Filho L). 2008 to present.

13. Thiago Buosi Silva. “Desenvolvimento e validação de nomogramas para estimar os

riscos de câncer de próstata e de câncer de próstata de baixo e alto grau de malignidade”.

FMUSP (Supervisor – Carvalho AL). 2010 to present.

14. Renato José da Silva Oliveira. “Identificação de novos biomarcadores preditivos da

resposta à terapia anti-EGFR em tumores sólidos. HCB (Supervisor – Reis RM; Co-supervisor

– Carvalho AL). 2011 to present.

7.2) Master Thesis

1. Adriana Cruvinel, projeto “Caracterização Citogenética e Molecular de Linhagens

Primárias de Gliomas”. HCB (Supervisor - Reis RM). 2011 to present.

2. Adriano Jander Ferreira, projeto: “Catalogação dos pacientes com diagnostico de

Sarcoma de Ewing tratados no Hospital de Câncer de Barretos”. HCB (Supervisor - Lopes LF).

2011 to present

3. Aline Caroline Camargo Mendonça, projeto: “Análise das características clínico -

epidemiológicas e de sobrevida dos casos de câncer pediátrico da Fundação Pio XII -

Hospital de Câncer de Barretos período de 2000 à 2011, HCB (Supervisor - Lopes LF). 2011 to

present.

4. Ana Laura Bordinhão Rodrigues, “Avaliação da expressão de microRNAs em linhagens

celulares de carcinoma mamário humano expostas a ação do fármaco Cediranib”. HCB

(Supervisor - Marques MMC). 2011 to present.

5. Augusto Ludvik Filip Marino, projeto “Análise do perfil de expressão diferencial de

microRNAs em carcinomas mamários por microarrays”. HCB (Supervisor - Marques MMC).

2011 to present.


6. Carla Aparecida Pinheiro, projeto “Estudo de Instabilidade Cromossômica e Correlação

com as Características Clinicopatológicas em Condrossarcomas”. HCB (Supervisor -

Camparoto ML) 2012 to present.

7. Croider Franco Lacerda, projeto “Estudo do gene supressor tumoral, TP53, no carcinoma

de células escamosas do esôfago associado ao megaesôfago chagásico” HCB (Supervisor -

Reis RM; Co-Supervisor Guimaraes DP). 2011 to present.

8. Emilze Mafra de Lima. Saúde oral como fator de risco para neutropenia febril pós-

quimioterapia em pacientes com neoplasias hematológicas. HCB. (Supervisor - Fregnani JH).

2011 to present.

9. Fernando Luís Visoni Poliseli – “Avaliação do número de cópias do gene TOP2A e da

expressão da sua proteína em leiomiossarcomas uterinos”. Hospital A.C. Camargo

(Supervisor - Fregnani JH) 2010-2012.

10. Flávia Coltri Eguchi, projeto “Avaliação da superexpressão das proteínas TMPRSS2 e

ERG e a fusão gênica TMPRSS2:ERG em portadores de câncer prostático”. HCB. (Supervisor -

Campos, SGP). 2011 to present.

11. Juliana Levy Daher, “Aspectos funcionais e emocionais da deglutição e fonação no

paciente com câncer de cabeça e pescoço pré e pós tratamento oncológico Hospital de

Câncer de Barretos” (HCB Supervisor - Carvalho AL). 2011 to present.

12. Letícia Rodrigues Cardoso. “Síndrome de Dor Miofascial em pacientes portadores de

câncer de cabeça e pescoço” HCB (Supervisor - Carvalho AL). 2011 to present.

13. Leticia dos Santos Yamane. “Estudo mutacional dos oncogeneses KRAS e BRAF nas

lesões do cólon e reto”. HCB (Supervisor – Guimaraes DG; Co-Supervisor Reis RM). 2011 to

present.

14. Luiz Cesar Záccaro da Silva. “Análise crítica da discrepância entre achados

histopatológicos da biópsia prostática realizada em centros não oncológicos e sua revisão

em um centro oncológico”. HCB (Supervisor - Scapualtempo-Neto, C). 2011 to present.

15. Maira DeGiovani Stein, projeto “Desempenho diagnóstico da citologia manual versus a

citologia assistida por computador usando BD FocalPoint GS Imaging system em material

preparado em sistema BD SurePath de base líquida”. HCB (Supervisor - Longatto Filho A).

2011 to present.


16. Natalia Campacci, projeto “Rastreamento populacional de famílias com predisposição

hereditária de câncer de mama e/ou câncer colorretal”. HCB (Supervisor - Palmero EI) 2011

to present.

17. Nathália Cristina Campanella. “Estudo da instabilidade de microssatélite e potenciais

genes alvos em GISTs”. HCB (Supervisor - Reis RM) 2012 to present.

18. Paulo Henrique Zanvettor – “Estudo de fatores prognósticos clínicos e biomoleculares

de pacientes portadores de câncer de vulva submetidos a tratamento cirúrgico”.

Universidade de São Paulo. (Supervisor - Fregnani JH). 2010-2012

19. Taciane Macedo, “Estudo funcional de microRNAs associados ao processo de metástase

em linhagens celulares de carcinoma mamário humano”. HCB (Supervisor - Marques, MMC)

2012 to present.

7.3) Trainee Fellows

1. André de Lima Mota, projeto Avaliação da expressão de VEGF e do seu receptor VEGFR-

1/Flt-1 e VEGFR-2/Flk-1 em linhagens celulares de carcinoma mamário humano expostas a

ação do fármaco Cediranib”. HCB (Supervisor - Marques MMC). 2012 to present.

2. Fernanda de Paula Cury. Análise do potencial risco de câncer na exposição dos

trabalhadores da construção civil a agentes carcinogênicos. HCB (Supervisor – Silveira HC).

2012 to present.

3. Graziela Sartori, projeto “Caracterização molecular em melanomas acrolentiginosos e das

mucosas.” HCB (Supervisor – Vazquez VL). 2012 to present.

4. Isabela de Carvalho, Projeto “Padronização e estabelecimento do Cultivo de amostras

tumorais de sarcomas humanos e análise da amplificação do centrossomo”. - HCB, HCB.

(Supervisor - Camparoto ML). 2011 to 2012.

5. Juliana Oliveira de Lima, Projeto “Rastreamento populacional de famílias com

predisposição hereditária de câncer de mama e/ou câncer colorretal”. HCB. (Supervisor-

Palmero EI). 2012 to present.

6. Lamis Ramadan. Desenvolvimento de estrategias educativas para famílias com

predisposição hereditária ao câncer de mama e/ou câncer colorretal. HCB. (Supervisor -

Palmero EI). 2012 to present.

7. Talitha Cezareti Blau Fonseca, projeto “Identificação de mulheres em risco para câncer

de mama hereditário por mutação nos genes BRCA1 e BRCA2: contribuição dos dados


patológicos, história familiar e modificadores genéticos do risco de câncer”. HCB (Supervisor

- Palmero EI). 2011 to present.

8) Prizes

1. Best oral communication at RNA Meeting, January 26th to 27th, 2012, Lisbon, Portugal.

Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Zhang X, Vannini I, Fanini F,

Fabbri M, Lanza G, Reis RM, Zweidler-McKay PA, Calin GA. Biological Effects of miR-28-5p

and miR-28-3p in colorectal cancer.

2. Best Poster on IV Scientific Meeting at Barretos Cancer Hospital. December 2012,

Barretos, SP, Brazil. Fernandes GC, Fonseca TCB, Michelli RD, de Paula DR, de Paula AE,

Viana DV, Scapulatempo-Neto C, Palmero EI. Triple Negative breast cancers and positive

family history are predictors of BRCA1 germline mutations.

3. Honor Mention Award to the Best communication in Human Cytogenetics at the 2nd

Paulista Cytogenetics Meeting para, Ribeirão Preto, São Paulo, Brazil – 2012. Laus AC, Santos

SA, Laureano LAF, Huber J, Squire JA, Martelli L. Molecular Cytogenetic Characterization of

Supernumerary Marker Chromosomes.

4. Honor Mention Award at IV Scientific Meeting of Barretos Cancer, December 2012,

Barretos, SP, Brazil. Cury FP, Schmidt-Carrijo M, Villegas CM, Seidel EH, Saldiva PH, Silveira

HCS. Assessing the genotoxicity of urban air quality in Barretos during the sugarcane burning

using Tradescantia micronucleus (Trad-MCN) bioassay.

5. Honor Mention Award to the student Cury FP because of the Best Initiation for Research

Fellows job at 58th National Genetic Congress, on September at Foz do Iguaçu. Assessing


Tradescantia micronucleus (Trad-MCN) bioassay. Cury FP, Schmidt-Carrijo M, Villegas CM,

Seidel EH, Saldiva PH, Silveira HCS.

6. Francisco Mauro Salzano Prize to the Best Human and Medicine Genetics work at the

58th National Genetic Congress in September, Foz do Iguaçu, Brazil. Marino ALF,

Evangelista AF, Longatto AF, Kerr LM, Vieira RAC, Macedo T, Silveira HCS, Marques MMC.

Differential expression profile of microRNAs during human breast cancer progression.

7. Travel awarded at 10th ICCB/16th SBBC Meeting. Rio de Janeiro, Brazil. Martinho O,

Pinto F, Granja S, Miranda-Gonçalves V, Moreira M, Ribeiro L, di Loreto C, Rosner M,


Longatto Filho A, Reis RM. Raf Kinase inhibitor (RKIP) depletion is associated with cervical

cancer

8. VII Prêmio Saúde Abril 2012– Women and Men Health. Using mobile and fixed units with

hereditary predisposition to breast cancer families. Campacci N, Viana DV, Michelli RD,

Mauad EC, Haikel Junior R, Reis RM, Carvalho AL e Palmero EI.

9) Participation in International Networks

1. Carvalho AL, Reis RM - International Cancer Genome Consortium. 2012 to present.

2. Carvalho AL, Marques MMC, Reis RM, Scapulatempo-Neto C - US-Latin American Cancer

Research Network (USLACRN). 2010 to present.

3. Carvalho AL, Mauad EC - WIN - World Innovative Networking, 2010 to present.

4. Carvalho AL - INTERCHANGE – Head and Neck Study Group (IARC), 2010 to present.

5. Mauad EC, Carvalho AL, Reis RM, Scapulatempo-Neto C – GAP – Global Academic

Program – Sister Institution Network (MDANderson). 2011 to present.

6. Reis RM - IMMEnSE (International Multiple Myeloma rESEarch) consortium – 2010 to

present.

7. Reis RM - Société Internationale d'Oncologie Pédiatrique (SIOP) - Brain Tumour

Committee- High Grade Glioma Working Group. 2010 to present.

10) Participation in National Networks

1. Carvalho AL - Scapulatempo-Neto C – GENCAPO – Projeto de Genoma Cabeça e Pescoço

Brazileiro, 2010 to present.

2. Palmero EI - Rede Brazileira de Câncer Familiar, 2010 to present.

3. Silveira HC – INAIRA - Instituto Nacional de Análise Integrada do Risco Ambiental (INCT),

2011 to present.

11) Organization of Conferences and Meetings

1. Lopes LF. 1a Jornada Interdisciplinar Regional em Oncologia Pediátrica, 2012.

2. Lopes LF. Simpósio Internacional de Oncologia Pediátrica, 2012.


3. Rossi BM. Especialização em Coloproctologia – Câncer Colorretal – Hospital Sírio Libanês –

Coordenador do Curso 2012.

4. Silveira HCS, Carvalho AL. Catâneo C. 2˚ Workshop de Meio Ambiente do Hospital de

Câncer de Barretos, 2012.

12) Lectures Executed / Seminars at Conferences and Meetings

1. Carvalho AL. Personalized Medicine for Head and Neck Cancer: Are we there yet? Global

Academic Program Meeting, May 14th to 16th 2012, Oslo, Norway.

2. Carvalho AL. Head and Neck Cancer Care in Brazil. 8th International Conference on Head

and Neck Cancer, Toronto, Canada.

3. Carvalho AL. Formação do Cirurgião de Cabeça e Pescoço - Pesquisa. I Jornada Acadêmica

Sul Brazileira de cirurgia de Cabeça e Pescoço. Florianópolis, Brazil.

4. Carvalho AL. Implicações da Infecção por HPV no Manejo do CEC da Orofaringe. 1o

Congresso Ítalo-Brazileiro de Cirurgia de Cabeça e Pescoço. Rio de Janeiro, Brazil.

5. Carvalho AL. Carcinoma Avançado de Laringe, Preservação da Laringe com Radioterapia +

Quimioterapia - Critérios Utilizados para Selecionar os Melhores Candidatos. Jornada Norte-

Nordeste de Cirurgia de Cabeça e Pescoço. Salvador, Brazil.

6. Carvalho AL. Porque a Mortalidade por Câncer de Laringe Avançado Aumentou nas

Últimas Décadas? Análise Crítica da Literatura. 2012. Jornada Norte-Nordeste de Cirurgia de

Cabeça e Pescoço. Salvador, Brazil.

7. Marques MMC. Biologia Tumoral: O que realmente está ao nosso alcance? IV Simpósio de

Mastologia, Oncologia, e Imagenologia Mamária de São José do Rio Preto, October 2012,

Universidade Paulista, São José do Rio Preto, SP, Brazil.

8. Reis RM. Câncer Gástrico Familiar. I Congresso Pan-Americano de Câncer Gástrico.

September 6-8 2012, Porto Alegre, Brazil.

9. Reis RM. Microsatellite Instabiltiy in Brain Tumors. Simpósio Internacional de Oncologia

Pediátrica, 25-26 de March, 2012, Barretos, SP, Brazil.

10. Rossi BM. Cirurgias pélvicas ampliadas – XVI Congresso Paraguaio de Cirurgia, Assunción,

Paraguay - Sep/2012.

11. Rossi BM. Discussão de casos clínicos: conselho dos mestres – XVI Congresso Paraguaio

de Cirurgia, Assuncion, Paraguay-Sep/2012.


12. Rossi BM. Tratamento da carcinomatose peritoneal – XVI Congresso Paraguaio de

Cirurgia, Assuncion, Paraguay-Sep/2012.

13. Rossi BM. Modelo de registro de cancer hereditário – XVI Congresso Paraguaio de

Cirurgia, Assuncion, Paraguay-Sep/2012.

14. Rossi BM. Câncer colorretal Hereditário – XVI Congresso Paraguaio de Cirurgia,

Assuncion, Paraguay-Sep/2012.

15. Rossi BM. Síndromes de polipose intestinal – Simpósio Internacional Endosur, Santiago,

Chile-Aug/2012.

16. Rossi BM. Síndrome de Lynch – Simpósio Internacional Endosur, Santiago, Chile -

Aug/2012.

17. Rossi BM. Câncer colorretal hereditário – I Congresso Internacional de Biologia

Molecular, Lima, Peru Nov/2012.

18. Rossi BM. Câncer colorretal hereditário – Sao Paulo Advanced School of Comparative

Oncology, São Paulo - Oct/2012.

19. Rossi BM. Organização do Meeting Internacional de 2015 em São Paulo – InSIGHT

Council Meeting, London, England – Dec./2012.

20. Rossi BM. Diagnóstico das síndromes hereditárias: FAP, MAP, síndrome de Lynch e

síndrome X – Especialização em Coloproctologia – Câncer Colorretal – Hospital Sírio Libanês,

São Paulo – Sep/2012.

21. Rossi BM. Manejo dos pacientes com síndrome de Lynch e síndrome X – Especialização

em Coloproctologia – Câncer Colorretal – Hospital Sírio Libanês, São Paulo – Sep/2012.

22. Rossi BM. Carcinogênese colorretal – Especialização em Coloproctologia – Câncer

Colorretal – Hospital Sírio Libanês, São Paulo – Mar/2012.

23. Silveira HC. Meio Ambiente, Agrotóxicos e Câncer. 1º Seminario sobre produção

orgânica. June 29th 2012, Câmara Municipal de Barretos, Barretos, SP, Brazil.

24. Silveira HC. Análise da queima da palha de cana-de-açúcar e suas relações com a

mutagenese humana. 01st November, 2012, Instituto Federal de Educação, Ciencia e

Tecnologia de São Paulo - Campus Barretos, SP, Brazil.

25. Silveira HC. Meio Ambiente e suas relações com o câncer, November29th, 2012,

Instituto Federal de Educação, Ciencia e Tecnologia de São Paulo - Campus Barretos, SP,

Brazil.


Vidal DO. Biologia molecular e genômica de tumores pediátricos. I Encontro Capixaba de

Biomedicina

26. Vidal DO. Biologia molecular e genômica de tumores pediátricos. I Encontro Capixaba de

Biomedicina: “Desafios e Perspectivas”, November 21st-23rd 2012, Vitória, ES, Brazil.

13) Funding

13.1) Governmental Agencies

1. Análise de metilação em câncer de cabeça e pescoço

Funding Agency: FAPESP

Duration: 2010-2013

PI: Eloiza Tajara, Members: André Lopes Carvalho, Matias MelenDec.

2. Avaliação do papel de microRNAs diferencialmente expressos no controle de invasão e

metástase do câncer de mama.


Duration: 2011-2013

PI: Marques MMC.

3. Avaliação da superexpressão das proteínas TMPRSS2 e ERG e a fusão gênica

TMPRSS2:ERG em portadores de câncer prostático .

Funding Agency: CNPq Universal

Duration: 2010-2012

PI: Silvana de Campos; Members: Longatto Filho A, Scapulatempo C.

4. “Identificaçao de mulheres em risco para cancer de mama hereditario: contribuiçao dos

dados anatomo-patologicos, historia familiar e polimorfismos geneticos para o

desenvolvimento do cancer de mama”.


Duration: 2010-2012

PI: Edenir I Palmero

5. “Chamada CNPq Nº 014/2011- Caracterização da instabilidade genômica em

glioblastomas: identificação e elucidação de novas vias moleculares em tumores e culturas

primárias”.



Duration: 2012-2013

PI: Reis RM; Members: Lucas Bidinotto, Adriana Curvini

6. “Fatores Preditivos de alterações citoarquiteturais induzidas pelo HPV após tratamento

cirúrgico de neoplasias intra-epiteliais do colo uterino”.


Duration: 2010-2012

PI: Fregnani JH; Members: Ismael Silva

7. Implantação do Centro de Pesquisa Translacional em Oncologia - Edital FINEP - CT-INFRA

- 02/2010.

Funding Agency: FINEP

Duration: 2010-2012

PI: Carvalho AL; Reis RM

8. Instituto Nacional de Ciência E Tecnologia para o estudo de papilomaviroses humanas.

Funding Agency: CNPq - Auxílio financeiro / FAPESP

Duration: 2009 – 2013

PI: Luisa Lina Villa, Member: Longatto Filho A

9. Prefeitura Municipal de Barretos (secretária de Meio Ambiente e Educação) (4.000,00)

Apoio ao projeto “Análise da queima da palha da cana-de-açúcar e suas relações com a

mutagênese humana”.

Duration: 02/2011 à 03/2012

PI: Silveira HC.

PI: Carvalho AL.

10. Rastreamento de biomarcadores e do Papilomavírus humano em raspado celular de

canal anal: correlação com infecção concomitante em colo uterino, cavidade oral e

orofaringe. Funding Agency: FAPESP

Duration: 01/2011 à 12/2012

PI: Longatto Filho A.

11. Implantação do Centro de Prevenção - Edital FINEP - CT-INFRA - 01/2012.

Funding Agency: FINEP

Duration: 2012-2013

PI: Carvalho AL; Longatto Filho A.

12. Decifrando o papel dos pyknons não-codificantes no câncer colorretal.


Funding Agency: SINF-MDAnderson Cancer Center

Duration: 2012-2014

PI: George Calin, Member: Rui M Reis

13. Avaliação do papel biológico e clínico de alterações nas vias moleculares RAS-MAPK e

PI3K-AKT, em melanomas cutâneos e de mucosa em população Brazileira e comparação

com a população estadunidense.

Funding Agency: FAPESP/fluxo continuo

Duration: 2012-2014

PI: Vazquez VL; Reis RM.

13.2) Pharmaceutical /Biotechnology Industry

1. “Estudo pré-clinico dos potenciais compostos anti-neoplásicos AM10 e AM11”.

Industry: Fitomedicamentos Amazônica

Duration: 2012-2014

PI: Reis RM.

13.3) Individual Grants

13.3.1) Technical Support

1. Edital MCT/CNPq 10/2010 - Apoio Técnico

Funding Agency: CNPq

Duration: 2010-2012

PI: André L. Carvalho

13.3.2) Master Fellowship

1. Beneficiary: Augusto Ludvik Filip Marino

Agency: FAPESP

Duration: 2012-2013

Responsible: Márcia MC Marques Silveira

2. Beneficiary: Nathália Cristina Campanella

Agency: FAPESP


Duration: 2012-2013

Responsible: Rui M Reis

3. Beneficiary: Flávia Coltri Eguchi

Agency: FAPESP Duration: 2012-2013

Responsible: Silvana Campos

13.3.3) Post-Doc Fellowship

1. Beneficiary: Lucas Bidinotto

Agency: FAPESP

Duration: 2011-2013

Responsible: Rui M Reis

2. Beneficiary: Adriane Feijó Evangelista

Agency: FAPESP

Duration: 2012-2014


3. Beneficiary: Matias Melen

Agency: CNPq

Duration: 2012-2014

Responsible: André Lopes Carvalho

13.3.4) Exchange Grants

1. Beneficiary: Augusto Ludvik Filip Marino

Agency: Government Canada- Internacional Scholarships (Emerging Leaders in the Americas

Program (ELAP) Duration: February a March de 2012

Country: Canada


2. Beneficiary: André van Helvoort Lengert

Agency: St. Jude Children’s Research Hospital Duration: July de 2012 a June de 2013.

Country: E.U.A.

Responsible: Daniel Onofre Vidal and Luiz Fernando Lopes.

13.3.5) Search Productivity Grant


1. Bolsista de Produtividade em Pesquisa 1D


CPOM-Hospital de Câncer de Barretos

Duration: 2011-2014

PI: Adhemar Longatto Filho

2. Bolsista de Produtividade em Pesquisa 2



Duration: 2011-2014

PI: Rui M Reis

3. Bolsista de Produtividade em Pesquisa 1D



Duration: 2010-2013

PI: André Lopes Carvalho

13.3.6) Visiting Professor

1. Funding Agency: CNPq

CPOM - Hospital de Câncer de Barretos

Visiting Professor: Kari Juhani Syrianny

Duration: 2012-20114

Responsable: Adhemar Longatto Filho

2. Funding Agency: CNPq


Visiting Professor: Jeremy Squire

Duration: 2011-2012

Responsable: André Lopes Carvalho

14) Jury participation

14.1) Academic Habilition

1. Rossi BM: Fábio de Oliveira Ferreira - Cirurgia Geral – Faculdade de Medicina da USP –

Substitute member – Dec./2012.


14.2) PhD

1. Lopes LF: Carolina Salinas de Souza- Investigação do comportamento metastático do

osteossarcoma através de análises de expressão gênica e de alterações genômicas. Tese de

Candidatura ao grau de Doutor em Ciências Médicas submetida à Universidade Federal de

São Paulo - Escola Paulista de Medicina.

2. Marques MMC: Aline Simoneti Fonseca- Assinatura gênica e de microRNAs (miRNAs)

entre adenoma e adenocarcinoma colorretal, Faculdade de Medicina de Ribeirão Preto/USP,

December 07th 2012, Ribeirão Preto, SP, Brazil.

3. Palmero EI: Ingrid Petroni Ewald- Caracterização de um grupo de pacientes em risco para

câncer de mama e ovário hereditários quanto à presença e frequencia de rearranjos genicos

em BRCA Universidade Federal do Rio Grande do Sul, June 11th, 2012, Porto Alegre, Brazil.

4. Reis RM: Marcus Valadao da Silva- Avaliação de potenciais biomarcadores preditores de

beneficio clinico ao mesilato de imatinibe em portadores de GIST metastático. INCA, May

2012, Rio de Janeiro, Brazil.

5. Reis RM: Joana Teresa Lopes Carvalho - O envolvimento de microRNAs em Cancro

Gástrico. Faculdade de Medicina da Universidade do Porto, December 2012, Porto, Portugal

6. Rossi BM: Ligia Petrolini de Oliveira – Correlação entre a presençaa de Splicing aberrante

e mutações sinônimas no gene TP53 em adenocarcinomas colorretais, Hospital A.C.Camargo

– FAP – São Paulo, Dec./2012.

7. Vazquez, V. L: Renato José Affonso Júnior - Estudo da expressão dos genes da matriz

extracelular MMP1, MMP16, COL6A2, THBS-1 E VCAM-1 no tecido tumoral de doentes com

adenocarcinoma colorretal e de suas correlações com os parâmetros clínicos e histológicos

de progressão e disseminação. 2012. - Universidade Federal de São Paulo.

14.3) Master

1. Guimarães DO: Maria de Lourdes Lopes de Oliveira, “Avaliação linfonodal e de seu valor

prognóstico no câncer de reto submetido a tratamento neoadjuvante”, INCA, August 2012,

Rio de Janeiro, Brazil.

2. Reis RM: Arthur William Alvarenga, “O controle da tradução pela via mTOR nos

mecanismos de tumorigenese em gliomas”, ACCamargo, September, 2012, S. Paulo, Brazil.


3. Reis RM: Ana Luísa Rodrigues Justino – Diagnostico genético das Síndromes associadas a

via de sinalização RAS/MAPK através de sequenciação paralela massiva e estudos de

correlações genótipo-fenótipo. Faculdade de Medicina da Universidade do Porto, December

2012, Porto, Portugal.

4. Rossi BM: Oswaldo William Marques Junior - Colonoscopia de Rastreamento em

Pacientes com Câncer.

15) National and International Collaborations:

15.1) National

- Centro Internacional de Pesquisa e Ensino (CIPE) - Hospital AC Camargo, S. Paulo.

- Faculdade de Medicina da Universidade de São Paulo, S. Paulo.

- INCT-HPV, S. Paulo.

- Instituto de Medicina Integral Professor Fernando Figueira/ Instituto Materno Infantil de

Pernambuco (IMIP), Recife, PE.

- Laboratório de Poluição Atmosférica da Faculdade de Medicina da USP.

- Universidade Federal de Goiás.

- Universidade Federal do Rio Grande do Sul, Porto Alegre.

15.2) International

- Harvard School of Public Health - HSPH, Boston, USA.

- Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Porto,

Portugal.

- Life and Health Science Research Institute (ICVS), University of Minho, Braga, Portugal.

- MDAnderson Cancer Center, Houston, USA.

- The Institute of Cancer Research (ICR), Sutton, UK.

- St. Jude Children’s Research Hospital, Memphis, TN, USA.

16. Visiting Researchers:

- Fábio Marques Almeida, PhD Student, UFG - Universidade Federal de Goiás, Brazil.

- Rui Pereira, Post-Doc. IPATIMUP, Porto, Portugal.

http://www.hsph.harvard.edu/


17. Molecular Diagnostics Center

The Molecular Diagnostics Center is offering to the Barretos Cancer Hospital patients a

variety of tests currently used in the clinical routine in the following areas: Cytogenetics,

Personalized Medicine and Oncogenetics.

18. Future Perspectives

Internal:

- Consolidation of the existing lines of research;

- Strengthen translational research;

-Increased the number of publications and projects by researcher

-Implement a Flow Citometry Service

External:

- Strengthen the partnerships with academic institutes, as well as with pharmaceutical and

biotechnology industry;

- Commercialization of tests from Molecular Diagnostics Center.

Molecular Oncology Research Center - Hospital de … Molecular Oncology Research Center – Barretos...

Documents

Transcript of Molecular Oncology Research Center - Hospital de … Molecular Oncology Research Center – Barretos...